Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...
Business Wire
More News
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates
Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Bayer (BAYRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform...
Yahoo! Finance: News
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio, Inc. (Nortiva) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX drug delivery platform. Nortivas LYNX platform can transform daily pills into long-acting oral therapies with single...
Business Wire
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddys for XACDURO in Select International Markets
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddys Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO...
Business Wire
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...
Business Wire
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Key PointsDauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter...
Nasdaq News: Markets

Advertisement|Remove ads.